ADCs forecast to capture $3.9 billion NSCLC market by 2032

The market for antibody-drug conjugates (ADCs) in non-small cell lung cancer (NSCLC) is poised for significant growth, projected to surpass $3.9 billion by 2032 across the USA, Europe, and Japan, according to data and analytics group GlobalData.

This expansion follows a prolonged period of limited ADC presence in NSCLC. Although the American medicines regulator approved Pfizer’s (NYSE: PFE) Mylotarg (gemtuzumab ozogamicin) in 2000, it wasn't until 2022 that the first ADC for NSCLC—AstraZeneca (LSE: AZN) and Daiichi Sankyo’s (TYO: 4568) Enhertu (trastuzumab deruxtecan)—received approval, targeting HER2-mutated tumors.

Since then, the development pipeline has accelerated. GlobalData anticipates a compound annual growth rate of 6.8% for ADCs in NSCLC across the seven major markets—USA, France, Germany, Italy, Spain, the UK, and Japan—driven by late-stage candidates nearing approval.